Biotin and Trastuzumab Interaction: Diagnostic Considerations

Introduction to Biotin Interference

• The American Society of Clinical Oncology emphasizes the need for accurate HER2 testing with proper quality control, as biotin can interfere with certain HER2 diagnostic assays, potentially leading to incorrect HER2 status determination 1
• Accurate HER2 testing is essential for selecting patients who will benefit from trastuzumab therapy, according to the National Comprehensive Cancer Network 1, 2

Diagnostic Interference and Testing Protocols

• Biotin can cause false results in streptavidin-biotin immunoassays used for HER2 testing, potentially leading to incorrect HER2 status determination 1
• HER2 status should be determined using standardized, validated assays (IHC 3+ or FISH amplification >2.0) to guide trastuzumab therapy, as recommended by the American Society of Clinical Oncology and the National Comprehensive Cancer Network 1, 2

Patient Management and Monitoring

• Patients should discontinue biotin supplements at least 72 hours (preferably 7 days for high doses) before any HER2 testing to avoid assay interference, according to the American Society of Clinical Oncology 1
• The primary monitoring concern with trastuzumab is cardiac toxicity, not biotin interaction, with a cardiotoxicity risk of 4% with trastuzumab monotherapy and 27% when combined with anthracyclines 4
• The European Society for Medical Oncology recommends that patients can continue biotin supplements during trastuzumab therapy without compromising treatment efficacy 3, 2

Treatment Initiation and Common Pitfalls

• Do not withhold trastuzumab due to biotin supplementation once HER2-positive status is properly confirmed, as early treatment provides maximum survival benefit, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 1, 2, 3, 5